Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 34Leukemia 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Hematologic Neoplasms 4Recurrence 3Neoplasms 2Thrombocytopenia 1Sarcoma, Myeloid 1Sarcoma, Kaposi 1Neoplasm, Residual 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Lymphoproliferative Disorders 1Lymphatic Diseases 1Leukemia, Myeloid 1Immunoproliferative Disorders 1HIV Infections 1Disease 1Congenital Abnormalities 1Acquired Immunodeficiency Syndrome 1

Interventions

dacetuzumab 6Rituximab 6blinatumomab 4ibrutinib 3Ifosfamide 3Bortezomib 3ponatinib 2cobomarsen 2Vorinostat 2Lenalidomide 2Etoposide 2Dexamethasone 2Carboplatin 2tetulomab tetraxetan lu-177 1pegaspargase 1ficlatuzumab 1enzalutamide 1durvalumab 1cirmtuzumab 1asparaginase erwinia chrysanthemi recombinant 1acalabrutinib 1Vincristine 1Prednisone 1Methotrexate 1Lutetium 1KW-2478 1Imatinib Mesylate 1Hsp90 inhibitor KU757 1Gemcitabine 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Immunoproliferative Disorders × Daunorubicin × Clear all
NCT02393859 2024-05-29

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Amgen

Phase 3 Completed
111 enrolled 23 charts 1 FDA
LymphoidOther hematologic neoplasm

Immunoproliferative Disorders, Lymphoproliferative Disorders, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡